A better way to make RNA drugs: Enzymatic synthesis method expands capabilities while eliminating toxic byproducts
General overview of the controlled, template-independent enzymatic RNA oligonucleotide synthesis process. Credit: Daniel J. Wiegand et al While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and amyloidosis. RNA therapies offer many advantages over traditional small molecule
Bong Howe
July 12, 2024